Patients with 2.2-fold change from baseline in placental growth factor ( n = 18 ) had significantly longer overall survival than those with < 2.2-fold change ( n = 19 ; 22.9 vs 7.9 months ; hazard ratio , 0.30 ; 95 % CI , 0.12-0 .74 ; P = 0.009 ) .